Amgen appoints Esteban Santos as executive VP of operations
June 20, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Amgen (NASDAQ: AMGN) has announced the appointment of Esteban Santos as executive vice president, operations. Santos will be responsible for …
Weekly Movers: Global Blood Therapeutics, Sophiris Bio…
June 20, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Global Blood Therapeutics, Shares, markets, pharma, stocks
Here’s a quick look at some of the biggest movers of the week:Sophiris Bio (Nasdaq: SPHS) stock rose to nearly …
Valeant plots significant investment in Canadian operations
June 20, 2016Manufacturing and Production, Sales and Marketing Canada, Valeant, manufacturing
Valeant Pharmaceuticals (NYSE: VRX) has announced that it plans to expand its Canadian operations with a $27.5 million expansion of …
NHS looking to offer free healthcare apps, devices from next year
June 20, 2016Medical Communications, Research and Development, Sales and Marketing DigitalHealth, HealthTech, NHS, NICE
The NHS will offer devices and apps for free to help patients manage their health, starting in UK next year.
GSK triple combo COPD therapy shows superiority in Phase III trials
June 20, 2016Research and Development, Sales and Marketing COPD, GSK, phase III
GlaxoSmithKline (LSE: GSK), along with Innoviva (NASDAQ: INVA), have presented positive top-line results from a pivotal Phase III trial for …
Chi-Med to get $10 million milestone from AstraZeneca after initiation of expanded Phase II trials in NSCLC
June 20, 2016Research and Development, Sales and Marketing AstraZeneca, Chi-Med, Iressa, Tagrisso, drug trial, lung cancer
Hutchison China MediTech (Nasdaq: HCM) on Monday said it is expanding Phase II trials in non-small cell lung cancer to …
Federal panel to review proposal for first human CRISPR test
June 20, 2016Research and Development, Sales and Marketing crispr, gene editing, human testing, oncology
A US Federal safety board is set to review a proposal for the first human use of the gene editing …
Synergy Vision MD appointed as trustee of the Cystic Fibrosis Trust
June 17, 2016Medical Communications Synergy Vision, appointment, cystic fibrosis, cystic fibrosis trust, medical communications, medical communications agency
Managing director of Synergy Vision Ffyona Dawber has been appointed to the Cystic Fibrosis Trust’s board of trustees. Her wealth …
Nice backs BMS’ combination immunotherapy Opdivo, Yervoy to treat skin cancer
June 17, 2016Medical Communications, Research and Development, Sales and Marketing BMS, NICE, oncology, opdivo, regulation, skin cancer
The National Institute for Health and Care Excellence (Nice) has backed a combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and …
Pfizer breaks ground on new $200 million biologics facility
June 17, 2016Medical Communications, Research and Development Manufacturing Facility, Pfizer
Pfizer (NYSE: PFE) has broken ground on a new $200 million biologics clinical manufacturing facility in Andover, Massachusetts. This expansion …
WellBe bracelet, mobile app to help manage stress
June 17, 2016Medical Communications, Research and Development HealthTech, WellBe, app, stress, wearable technology
Adding to the growing list of healthcare applications, a new technology claims to have created the first anti-stress biofeedback bracelet …
Merck & Co says Keytruda shows better results than chemotherapy in Phase III trials for lung cancer
June 17, 2016Medical Communications MSD, Merck & Co, drug trial, keytruda, lung cancer
US drug major Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced non-small-cell …
Final Nice appraisal says no to cystic fibrosis drug, Orkambi
June 17, 2016Medical Communications NICE, Orkambi, Vertex Pharma, cystic fibrosis, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) has issued a final appraisal determination rejecting cystic fibrosis drug, Orkambi …
Roche gets a NICE knockback for melanoma drug, Cotellic
June 16, 2016Medical Communications, Research and Development, Sales and Marketing Cotellic, NICE, Roche
The National Institute for Health and Care Excellence (NICE) has announced that that it has not recommended Roche’s melanoma drug, …
SMC recommends treatment for potentially fatal chemotherapy-related disease
June 16, 2016Research and Development, Sales and Marketing Menarini, SMC, adneuric
The Scottish Medicines Consortium has recommended Adenuric (febuxostat), a treatment for a severe complication that can affect chemotherapy patients in …
Chiasma cuts staff by 33% after FDA rejects rare disease drug, Mycapssa
June 16, 2016Research and Development, Sales and Marketing FDA, chiasma, cutbacks, failure, workforce cuts
US-based biopharmaceutical company, Chiasma (NASDAQ: CHMA), has announced substantial job cuts as it attempts to restructure following the US Food …
UK biotech in great shape, according to new industry report
June 16, 2016Research and Development Europe, UK, biotech, uk bioindustry association
The UK biotechnology sector is going from strength to strength, having raised an “unprecedented” £900 million on the London Stock …
Roche secures EU approval for Gazyvaro in new lymphoma indication
June 16, 2016Research and Development, Sales and Marketing EU, Gazyvaro, Roche, follicular lymphoma
Roche (SIX: RO) has announced that the European Commission has approved Gazyvaro (obinutuzumab), in combination with bendamustine chemotherapy, in patients …
Teva returns rights to heart cell therapy to Mesoblast
June 16, 2016Research and Development, Sales and Marketing Mesoblast, Teva, chronic heart failure, phase III
Israeli drugmaker Teva (NYSE: TEVA) has returned full rights to a drug for heart condition in late stage trials to …
Marathon Pharma submits application for Duchenne muscular dystrophy drug to FDA
June 15, 2016Research and Development, Sales and Marketing FDA, duchenne, marathon pharmaceuticals
Marathon Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
